Severe Case of Thrombotic Microangiopathy with a Delayed Diagnosis of Atypical Haemolytic Uraemic Syndrome Successfully Managed with Eculizumab

  • Duaa Aresmouk Nephrocare Hagen GmbH
DOI: https://doi.org/10.12890/2015_000180

Keywords

Chronic kidney disease, eculizumab, hemolytic uremic syndrome

Abstract

Objectives: To describe the diagnosis and treatment of a severely ill patient presenting with thrombotic microangiopathy (TMA) of unknown cause.

Case presentation: An adult female presented to intensive care with abdominal pain and haemorrhagic shock, requiring reanimation.

Results: Features of TMA were present, but initial plasma exchange was ineffective. Treatment with the anti-C5 antibody, eculizumab, improved laboratory parameters and organ function, albeit slowly. Eculizumab remains effective and well tolerated after 30 months of treatment.

Conclusion: This case demonstrates the complexities and importance of early identification of atypical haemolytic uraemic syndrome in patients presenting with TMA.

VIEW THE ENTIRE ARTICLE

References

  • Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013;33:27–45.
  • Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565.
  • Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643–657.
  • Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169– 2181.
  • Povey H, Vundru R, Junglee N, Jibani M. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol 2013;82:326–331.
  • Duran CE, Blasco M, Maduell F, Campistol JM. Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome. Clin Kidney J 2012;5:28–30.

    • Published: 2015-03-25

    Issue: Vol. 2 No. 2 (2015) (view)

    Section: Articles

    How to cite:
    1.
    Aresmouk D. Severe Case of Thrombotic Microangiopathy with a Delayed Diagnosis of Atypical Haemolytic Uraemic Syndrome Successfully Managed with Eculizumab. EJCRIM 2015;2 doi:10.12890/2015_000180.